Board Meeting Outcome

Net loss reportedRevenue declinedNegative operating cash flowResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.6%Reaction day

₹10.65

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.1%-0.7% vs market

Pharmaceuticals peers, median of 147sector-0.1%-0.5% vs sector

On the reaction day the stock moved 0.7 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.6+0.1-0.7-0.1-0.5

Next day

-3.8-0.2-3.6-0.2-3.6

-0.5+0.3-0.8-0.2-0.2

+2.8+0.9+2.0+0.0+2.8

+7.7+0.8+6.9+0.0+7.7

+11.2+2.2+9.0+0.6+10.6

+4.3+3.4+0.9+1.4+2.9

15d

-5.1-0.8-4.3-2.9-2.1

-0.4+2.9-3.3+0.3-0.6

-1.2+0.8-2.1-0.4-0.9

-6.3+0.0-6.3-3.2-3.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Vista Pharmaceuticals reported audited results for FY25 with revenue from operations of ₹1,007.46 lakhs, a slight decline of about 2% from ₹1,028.78 lakhs in FY24. The company posted a net loss of ₹464.87 lakhs for FY25, widening from a loss of ₹451.20 lakhs in the previous year, with EPS of ₹(0.79). Q4 FY25 revenue grew sharply to ₹323 lakhs from ₹255.5 lakhs in Q4 FY24, but the company still reported a quarterly loss of ₹149.57 lakhs. Operating cash flow was deeply negative at ₹(698.46) lakhs, while the company raised fresh funds through share capital and borrowings to shore up liquidity. The statutory auditor issued an unmodified/unqualified opinion, and the board also appointed new internal and secretarial auditors. The company noted it has received WHO certification.

Likely market impact

Persistent losses, deeply negative operating cash flow, and reliance on fresh equity and borrowings to stay afloat are negative signals for shareholders. While the auditor gave a clean opinion and revenue grew strongly in Q4, the full-year picture remains weak with widening losses.